Search Within

Hamza Hashmi

Formats
  1. Meeting Abstract (41)
  2. Journal Article (14)
  3. Research Letter (3)
  4. Correspondence (2)
  5. Review (2)
  6. Editorial (1)
Groups
  1. Hematologic Malignancies, Division of (31)
  2. Center for Hematologic Malignancies (30)
  3. Department of Medicine (30)
  4. Bone Marrow Transplant (29)
  5. Survivorship Research (29)
  6. Myeloma (28)

More Groups

People
  1. Saad Usmani (30)
  2. Sridevi Rajeeve (30)
  3. Sham Mailankody (28)
  4. Heather Landau (26)
  5. Alexander Lesokhin (25)
  6. Carlyn Rose Tan (25)

More People

Years
  1. 2025 (11)
  2. 2024 (52)
Publications
  1. Blood (29)
  2. Clinical Lymphoma, Myeloma and Leukemia (16)
  3. Blood Cancer Journal (4)
  4. Blood Advances (3)
  5. European Journal of Haematology (2)
  6. Transplantation and Cellular Therapy (2)

More Publications

Publishers
  1. American Society of Hematology (32)
  2. Elsevier Inc. (18)
  3. Nature Publishing Group (4)
  4. John Wiley & Sons (3)
  5. American Society of Clinical Oncology (1)
  6. Biomed Central Ltd (1)

More Publishers

Results (63)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in relapsed or refractory multiple myeloma
    Meeting Abstract

    Hansen, D. K.; Peres, L. C.; Dima, D.; Richards, A.; Shune, L. O.; Afrough, A.; Midha, S.; Dhakal, B.; Kocoglu, M. H.; Atrash, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; GarceĢs, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Evaluation of teclistamab in BCMA-directed therapy exposed versus naive in relapsed/refractory multiple myeloma
    Meeting Abstract

    Snyder, J.; Graf, K.; Davis, J. A.; McKenna, M.; Tiger, Y. K.; Laharwal, M. M.; Mewawalla, P.; Alkharabsheh, O.; Hashmi, H.; Shaikh, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A real-world analysis of the safety and efficacy of teclistamab for patients with relapsed/refractory multiple myeloma and baseline renal impairment
    Meeting Abstract

    Habib, A.; Khan, A. M.; Laharwal, M. M.; Mewawalla, P.; McKenna, M.; Tiger, Y. K.; Shaikh, H.; Strouse, C.; Green, K. M.; Davis, J. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world efficacy outcomes of ciltacabtagene autoleucel in relapsed refractory multiple myeloma: A with the CARTITUDE-1 trial
    Meeting Abstract

    Kamboj, I.; Chang, D. R. Y.; Habib, A.; Vegel, A.; Struble, E.; Shaikh, H.; Strouse, C.; Davis, J. A.; Rashid, A.; Graf, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy of daratumumab, pomalidomide and dexamethasone compared to daratumumab, carfilzomib and dexamethasone in high risk relapsed multiple myeloma: multicenter real-world experience
    Meeting Abstract

    Magee, G.; Mansour, R.; Chang, M. R.; Atrash, S.; Ahmed, N.; Mushtaq, M. U.; Ouchveridze, E.; Abdallah, A.; Paul, B.; Green, K. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save